: iStockAnalyst.com Symbols Feed

Is Cheap Growth Still Available After Rally?

Mon, 12 Oct 2009 15:19:14 GMT

This was the theme behind my latest stock screen. After the massive run-up, investors need to be careful that laggards were not left behind for good reason. So I screened for cheap stocks relative to their expected growth rates while requiring high return on assets (ROA) and return on equity (ROE).[More...]

Insider Buys and Sells: Weekly Wrap-up - 09-08-2009

Tue, 08 Sep 2009 12:56:44 GMT

For all the analysts and pundits in the financial media, there is still no better judge of a company's health and future prospects than the owners and executives of those companies themselves, along with major institutional shareholders.[More...]

Wall Street Ends Up in Choppy Session, General Electric (NYSE: GE) Drops

Wed, 26 Aug 2009 21:25:12 GMT

US stocks mustered only tiny gains on Wednesday, despite stronger-than-expected durable goods and housing data.[More...]

US Stock Futures Mixed After Orders Data, Dollar Tree (NASDAQ: DLTR) Eyed

Wed, 26 Aug 2009 12:55:40 GMT

US stock futures were mixed on Wednesday even as a government release showed orders for durable goods jumped 4.9% in July, the biggest increase in two years.[More...]

Spotlight On: Biotech

Sun, 09 Aug 2009 19:06:17 GMT

Spotlight On: Biotech The U.S. biotechnology industry includes about 1,000 companies, of all sizes, with combined annual revenues close to $50 billion. Large companies include Amgen, Biogen Idec, Genetech, Genzyme, Life Technologies and Monsanto. Because so many drugs are now developed using biotechnology, the biotech and pharmaceutical industries overlap. Demand for biotechnology products and services is driven primarily by the willingness of insurers to pay for new medical treatments. With the pending introduction of Obamacare, new uncertainties are introduced to this industry. Biotech products and treatments tend to be expensive and the drive to reduce costs through rationing will no doubt effect this industry. The profitability of individual companies depends on the discovery and effective marketing of new products. Because the market for potential[More...]

Stocks Log Narrow Gains After Mixed Data, Oil's Drop Back Below $70

Wed, 01 Jul 2009 20:25:00 GMT

The major stock averages close up just under 1%, but well off the day's highs.[More...]

Myriad Genetics (Nasdaq: MYGN) Implodes After Hours on Revenue Miss

Wed, 01 Jul 2009 14:52:00 GMT

How far Myriad Genetics (MYGN) has fallen - this had been one of the star stocks of the last 12 months as it seemed to do no wrong. In fact during 2 of the worst swoons in market history (Sep-Oct 08, and Jan-Feb 09) the stock held its ground and/or advanced! But the past few months have not treated it kindly. Last night after the bell Myriad came out with a "slight" revenue warning - $86M for fiscal fourth quarter (analysts had estimated $91.6M as consensus); so a 6% shortfall. This miss takes them to a $326M year versus prior guidance of $330M, and analysts $336M. For that the stock was down 17%+ in after hours yesterday. It seems overdone but a few issues here (1) this is the second "miss" by management in a short period of time (2) the stock has been expensive even with the dramatic drop since late winter and (3)[More...]

Stocks Headed Higher As Wall Street Takes ADP's Preview Of Jobs Report In Stride

Wed, 01 Jul 2009 12:55:00 GMT

U.S. stock futures maintain pre-market gains in the wake of an ADP report showing private companies shed 473,000 jobs in June.[More...]

Biotech Industry Overview

Mon, 01 Jun 2009 14:38:59 GMT

The Biotech industry as a whole continues to underperform the market so far this year. As of May 26, 2009, Both the AMEX Biotech Index and the broader NASDAQ Biotech Index declined 6.8% (AMEX Biotech has 20 biotech companies while NASDAQ Biotech Index inc[More...]

Buy Myriad Genetics (Nasdaq: MYGN), Post-Results

Wed, 06 May 2009 17:03:00 GMT

Fiscal 2009 third quarter financial performance remains strong Myriad Genetics, Inc. (MYGN) relies on its molecular diagnostic products for its revenue generation and is currently seeing solid growth in this business. On May 4, 2009, the company reported fiscal 3Q09 financial results ended March 31, 2009. Total revenue for the 2009 fiscal third quarter increased to a record $87.5 million, compared with $61.8 million in the prior-year period. Molecular diagnostic revenues rose 47% to $86.5 million from $59.0 million last year. The improvement resulted primarily from an increase in the Company's sales and[More...]

Myriad Posts Higher Revenue, Earnings: SLC Firm Optimistic About Diagnostic Products.

Wed, 26 Aug 2009 17:51:00 GMT

Aug. 26--Myriad Genetics Inc. reported Tuesday that revenue generated from its molecular diagnostic products reached $327 million during its 2009 fiscal year, a 47 percent increase over its sales in fiscal 2008.
The Salt Lake City-based company, which sells genetic tests that help health care providers determine if someone has a predisposition to diseases such as breast and ovarian cancer, said its net income for the years was $84.6 million, or 86 cents per share.
"Looking at the year more closely, the current economic recession began to impact our revenue growth during the second half of the year, with first half growth of 55 percent decelerating to 40 percent in the second half of the year," Peter Meldrum, Myriad's chief executive said in a conference call with investors.

: iStockAnalyst.com Symbols Feed

Is Cheap Growth Still Available After Rally?

Insider Buys and Sells: Weekly Wrap-up - 09-08-2009

Wall Street Ends Up in Choppy Session, General Electric (NYSE: GE) Drops

US Stock Futures Mixed After Orders Data, Dollar Tree (NASDAQ: DLTR) Eyed

Spotlight On: Biotech

Stocks Log Narrow Gains After Mixed Data, Oil's Drop Back Below $70

Myriad Genetics (Nasdaq: MYGN) Implodes After Hours on Revenue Miss

Stocks Headed Higher As Wall Street Takes ADP's Preview Of Jobs Report In Stride

Biotech Industry Overview

Buy Myriad Genetics (Nasdaq: MYGN), Post-Results

Myriad Posts Higher Revenue, Earnings: SLC Firm Optimistic About Diagnostic Products.

Davidson 99 Firms Exceed Dow, S&P: Index Strengthened By Exposure to Consumer, Tech Markets in Region

Analyst Picks and Pans: Nasdaq, Myriad Genetics, Sealy

AIG, General Mills, MetroPCS are big movers

Patenting Human Genes Thwarts Research, Scientists Say

ACLU sues over cancer gene patents

ACLU sues over cancer gene patents

Utah Stocks: Some Bright Spots Amid the Gloom

Northwest Stocks Hit Hard

Two Utah Companies Post Stunning Gains During 2008: Best and Worst ? But Most on Index Show Big Declines

Myriad Pharmaceuticals Reports First Quarter FY' 2010 Financial Results

EpiCept Corporation Reports Third Quarter Results,Provides Business Update

Myriad Genetics Reports First Quarter Fiscal 2010 Financial Results; Revenue Grows 22%; Net Income Rises 111% Compared to Prior Year

Nasdaq Panel Grants EpiCept's Request for Continued Listing

Myriad Genetics Elects Louise Phanstiel and Lawrence Best to Its Board of Directors

Myriad Genetics Reports Fiscal 2009 Financial Results; Net Income Rises 77%, Product Revenue Up 47%

Myriad Genetics Reports Fiscal 2009 Financial Results

EpiCept Corporation Reports Second Quarter 2009 Operating and Financial Results, Provides Business Update

Myriad Genetics to Report Fiscal 2009 Fourth Quarter and Year-End Financial Results On August 25

PDI Appoints Gerald P. Belle As Lead Independent Director

Form 4 WILSON LINDA S For: Nov 05 (10K)

Form 4 MYRIAD GENETICS INC For: Nov 05 Filed by: LANGER DENNIS (10K)

Form 4 MYRIAD GENETICS INC For: Nov 04 Filed by: SKOLNICK MARK H (10K)

Form 4 GILBERT WALTER PHD For: Nov 05 (10K)

Form 4 HENDERSON JOHN T For: Nov 05 (10K)

Form 4 MYRIAD GENETICS INC For: Nov 04 Filed by: Belle Gerald P. (10K)

Form 4 MYRIAD GENETICS INC For: Aug 28 Filed by: MELDRUM PETER D (10K)

Form 4 CRITCHFIELD GREGORY C For: Sep 15 (10K)

Form 4 MYRIAD GENETICS INC For: Sep 15 Filed by: Evans James S (10K)

Form 4 MARSH RICHARD M For: Sep 15 (10K)